TABLE 3.

Change in the TAPSE Between Baseline and 6 mo Follow-up

Variable	Total	Baseline	6 mo	P
Titration dose
49/51 mg	N = 22	13.9 ± 2.6	16.8 ± 4.1	<0.001
24/26 mg	N = 56	13.4 ± 3.3	15.8 ± 4.7	0.013
12/13 mg	N = 4	15.3 ± 2.6	17.4 ± 1.6	0.046
NYHA class
II	N = 22	13.2 ± 2.6	16.1 ± 2.8	0.002
III	N = 41	14.3 ± 2.1	16.6 ± 4.8	0.026
IV	N = 19	13.0 ± 2.1	16.7 ± 4.5	0.005
Gender
Male	N = 61	13.5 ± 2.3	15.8 ± 4.5	0.001
Female	N = 21	14.2 ± 2.3	16.6 ± 3.7	0.035
Hypertension
Yes	N = 21	14.5 ± 2.3	17.1 ± 4.3	0.043
No	N = 61	13.4 ± 2.2	15.6 ± 4.2	0.001
Diabetes
Yes	N = 14	14.4 ± 1.8	18.0 ± 3.9	0.016
No	N = 68	13.5 ± 2.4	15.5 ± 4.2	0.001
MI
Yes	N = 8	13.7 ± 1.9	17.5 ± 4.9	0.036
No	N = 74	13.7 ± 2.3	15.8 ± 4.2	<0.001
PASP >60 mm Hg
Yes	N = 22	13.5 ± 2.4	15.9 ± 3.3	0.012
No	N = 60	13.7 ± 2.3	16.0 ± 4.5	0.001
CRTP/CRTD
Yes	N = 24	14.5 ± 2.6	16.4 ± 3.6	0.046
No	N = 58	14.2 ± 3.1	16.3 ± 4.6	0.001

Values are presented as mean ± SD. P values <0.05 were considered statistically significant.

CRT-D, cardiac resynchronization therapy–defibrillator; CRTP, cardiac resynchronization therapy pacemaker.